Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

28
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

43.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

563
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
563
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

42
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort.

JHEP reports : innovation in hepatology·2026
Same author

Hepatocellular Carcinoma Treatment with Immune Checkpoint Inhibitors: RECA and CRAFITY Scores Reveal Distinct Clinical Courses and Highlight the Role of Systemic Inflammation in Prognosis.

Biomedicines·2026
Same author

Delta Describe, the French Collaborative Project: The Profile and Management of Hepatitis Delta Patients in Metropolitan France.

Viruses·2026
Same author

Predicting hepatocellular carcinoma in people with hepatitis B: a comparison between Cox proportional hazard and machine learning models.

Journal of epidemiology and population health·2026
Same author

Steatosis severity and metabolic fingerprints after HCV eradication: toward an individualised approach to HCC surveillance after HCV cure.

Gut·2026
Same author

Predictive Value of Sustained Virologic Response at Week 4 in Patients with Hepatitis C Virus Infection Treated with Sofosbuvir/Velpatasvir.

Viruses·2026

Related Experiment Video

Updated: May 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K

Chronic hepatitis C: future treatment.

Astrid Wendt1, Xavier Adhoute1, Paul Castellani1

  • 1Department of Hepato-Gastroenterology, Hôpital Saint-Joseph, Marseille, France.

Clinical Pharmacology : Advances and Applications
|January 29, 2014
PubMed
Summary

New direct-acting antiviral agents, including nucleoside/nucleotide and NS5A inhibitors, offer potent, pan-genotypic activity for Hepatitis C Virus (HCV) treatment, improving outcomes for all patients.

Keywords:
SVRcirrhosisdirect antiviral agentshost-targeting agentsinterferon-free regimenpangenotypic activity

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Experiment Videos

Last Updated: May 3, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

7.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • First-generation protease inhibitors (PIs) advanced Hepatitis C Virus (HCV) treatment, primarily for genotype 1 (GT-1).
  • Subsequent PI generations offer improved potency, broader genotype activity, better tolerability, and activity against resistant strains.
  • Nucleoside/nucleotide inhibitors (NIs) and NS5A inhibitors (NS5A.I) demonstrate high efficacy across all HCV genotypes.

Purpose of the Study:

  • To provide an overview of recent clinical results in Hepatitis C Virus (HCV) treatment.
  • To highlight advancements in direct-acting antiviral (DAA) therapies.
  • To discuss the potential of new combination regimens for HCV cure.

Main Methods:

  • Review of clinical trial data for novel HCV therapeutic agents.
  • Analysis of efficacy and safety profiles of second-generation PIs, NIs, and NS5A.I.
  • Evaluation of interferon-free and interferon-based regimens, including combinations with pegylated interferon and ribavirin (PR).

Main Results:

  • Sofosbuvir (a NI) shows potent pan-genotypic activity with PR, enabling shorter treatment durations.
  • Interferon-free regimens combining NS5A.I and PIs can cure GT-1b null responders.
  • DAA combinations, including pan-genotypic NIs and NS5A.I, significantly increase sustained virological response rates for all patients, including those with cirrhosis.

Conclusions:

  • The development of pan-genotypic direct-acting antiviral agents (DAAs) revolutionizes HCV treatment possibilities.
  • New combination therapies, with or without PR, offer high cure rates across all genotypes and patient populations.
  • The future of Hepatitis C Virus (HCV) treatment is highly promising, with potential for universal cure.